6th Sep 2016 09:53
LONDON (Alliance News) - Gene-editing technology developer Horizon Discovery Group PLC on Tuesday said it has signed a collaboration with US-based Fulcrum Therapeutics to use Horizon's CRISPR-based screening platform.
The platform helps to examine the regulation of genes and the role they play in disease. Under the collaboration, Horizon will use the platform to help Fulcrum in developing a new range of therapeutic treatments.
"This partnership confirms Horizon's role as a preferred partner not only for established biotechnology and pharmaceutical companies, but also for start-ups looking for long-term collaborations rather than having to build in-house capabilities," said Darrin Disley, Horizon's chief executive.
Shares in Horizon were flat at 169.00 pence on Tuesday.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
HZD.L